[
  {
    "ts": null,
    "headline": "Edwards Makes A Bullish Move As Heart-Valve Replacements Top $1 Billion",
    "summary": "Edwards Lifesciences stock popped Wednesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat.",
    "url": "https://finnhub.io/api/news?id=0958ad7a17960f1900f055b6207dd5dd3887f2ccc054eaa97b94c802499c111f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739394908,
      "headline": "Edwards Makes A Bullish Move As Heart-Valve Replacements Top $1 Billion",
      "id": 132829427,
      "image": "https://media.zenfs.com/en/ibd.com/33c71d0ba81602b08aa36aed679caf6f",
      "related": "EW",
      "source": "Yahoo",
      "summary": "Edwards Lifesciences stock popped Wednesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat.",
      "url": "https://finnhub.io/api/news?id=0958ad7a17960f1900f055b6207dd5dd3887f2ccc054eaa97b94c802499c111f"
    }
  },
  {
    "ts": null,
    "headline": "Heart Devices-Focused Edwards Lifesciences Confident in 2025 Outlook, Analyst Sees Long-Term Strength",
    "summary": "On Tuesday, Edwards Lifesciences (NYSE:EW) reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This represents a 9% year-over-year growth, supported by gains in all product groups. Adjusted earnings per share came in at 59 cents, compared to analysts’ estimate of 55 cents. Transcatheter Aortic Valve Replacement (TAVR) global sales grew 5.3% year-over-year to $1.04 billion in the fourth quarter. Transcatheter Mitral and Tricuspid Therapies (TMTT) sales reached",
    "url": "https://finnhub.io/api/news?id=490f9c2d93865572971e03f26b5486c46039fd5a93c098249a680962519e7635",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739389870,
      "headline": "Heart Devices-Focused Edwards Lifesciences Confident in 2025 Outlook, Analyst Sees Long-Term Strength",
      "id": 132829428,
      "image": "https://media.zenfs.com/en/Benzinga/42ea4675dbb5d0a26d1792f390504498",
      "related": "EW",
      "source": "Yahoo",
      "summary": "On Tuesday, Edwards Lifesciences (NYSE:EW) reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This represents a 9% year-over-year growth, supported by gains in all product groups. Adjusted earnings per share came in at 59 cents, compared to analysts’ estimate of 55 cents. Transcatheter Aortic Valve Replacement (TAVR) global sales grew 5.3% year-over-year to $1.04 billion in the fourth quarter. Transcatheter Mitral and Tricuspid Therapies (TMTT) sales reached",
      "url": "https://finnhub.io/api/news?id=490f9c2d93865572971e03f26b5486c46039fd5a93c098249a680962519e7635"
    }
  },
  {
    "ts": null,
    "headline": "Edwards Lifesciences Corp. stock outperforms competitors on strong trading day",
    "summary": "Edwards Lifesciences Corp. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=1e4898b0896fe1fa027dd8e7c15819193c7113b46016b987b0affa3a2212ffb1",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739377800,
      "headline": "Edwards Lifesciences Corp. stock outperforms competitors on strong trading day",
      "id": 132689674,
      "image": "",
      "related": "EW",
      "source": "MarketWatch",
      "summary": "Edwards Lifesciences Corp. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=1e4898b0896fe1fa027dd8e7c15819193c7113b46016b987b0affa3a2212ffb1"
    }
  },
  {
    "ts": null,
    "headline": "Q4 2024 Edwards Lifesciences Corp Earnings Call",
    "summary": "Q4 2024 Edwards Lifesciences Corp Earnings Call",
    "url": "https://finnhub.io/api/news?id=97eb7cd4c873e15f9b518fce15e8dec204ce03b70922918518555a49c1f4d357",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739372150,
      "headline": "Q4 2024 Edwards Lifesciences Corp Earnings Call",
      "id": 132829429,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "Q4 2024 Edwards Lifesciences Corp Earnings Call",
      "url": "https://finnhub.io/api/news?id=97eb7cd4c873e15f9b518fce15e8dec204ce03b70922918518555a49c1f4d357"
    }
  },
  {
    "ts": null,
    "headline": "Is Edwards Lifesciences Corporation (EW) the Best Medical Device Stock to Buy?",
    "summary": "We recently published a list of the 10 Best Medical Device Stocks To Buy According to Hedge Funds. In this article, we are going to take a look at where Edwards Lifesciences Corporation (NYSE:EW) stands against other best medical device stocks to buy right now. Overview of the Medical Devices Sector According to a report […]",
    "url": "https://finnhub.io/api/news?id=e22bc3792413128cb9957b972f6af225a8d6f023ac83c3b14b94248457999b0e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739369771,
      "headline": "Is Edwards Lifesciences Corporation (EW) the Best Medical Device Stock to Buy?",
      "id": 132829430,
      "image": "https://s.yimg.com/ny/api/res/1.2/r5wb8Ka0kq8R6ElVqKw.7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/b3057a7754527818c994a28a0dacb15b",
      "related": "EW",
      "source": "Yahoo",
      "summary": "We recently published a list of the 10 Best Medical Device Stocks To Buy According to Hedge Funds. In this article, we are going to take a look at where Edwards Lifesciences Corporation (NYSE:EW) stands against other best medical device stocks to buy right now. Overview of the Medical Devices Sector According to a report […]",
      "url": "https://finnhub.io/api/news?id=e22bc3792413128cb9957b972f6af225a8d6f023ac83c3b14b94248457999b0e"
    }
  },
  {
    "ts": null,
    "headline": "Edwards Lifesciences (NYSE:EW) Is Reinvesting At Lower Rates Of Return",
    "summary": "Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want...",
    "url": "https://finnhub.io/api/news?id=9b5920723807243cf2e4fda0e02f8e7d419696c20c5f7a525c614ac156eaf407",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739365221,
      "headline": "Edwards Lifesciences (NYSE:EW) Is Reinvesting At Lower Rates Of Return",
      "id": 132829431,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/983f2bdfe32b19227b1d118c45bf4f09",
      "related": "EW",
      "source": "Yahoo",
      "summary": "Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want...",
      "url": "https://finnhub.io/api/news?id=9b5920723807243cf2e4fda0e02f8e7d419696c20c5f7a525c614ac156eaf407"
    }
  },
  {
    "ts": null,
    "headline": "Edwards predicts second-half lift from TAVR label expansion",
    "summary": "Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this year.",
    "url": "https://finnhub.io/api/news?id=b251484ed96eb6944bdfb10647f71308574471fd8789f6ac9c3acbcf70d3810a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739358000,
      "headline": "Edwards predicts second-half lift from TAVR label expansion",
      "id": 132829432,
      "image": "https://imgproxy.divecdn.com/yB5p5lUL0elR-kYmhMSW3mxjsCw-S_MzikN0eKthiPg/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9pcnZpbmUtY2FtcHVzLmpwZw==.webp",
      "related": "EW",
      "source": "Yahoo",
      "summary": "Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this year.",
      "url": "https://finnhub.io/api/news?id=b251484ed96eb6944bdfb10647f71308574471fd8789f6ac9c3acbcf70d3810a"
    }
  },
  {
    "ts": null,
    "headline": "Edwards Lifesciences Corp (EW) Q4 2024 Earnings Call Highlights: Strong Full-Year Growth and ...",
    "summary": "Edwards Lifesciences Corp (EW) reports robust 9% sales growth for 2024, driven by TMTT segment and strategic acquisitions, despite regional challenges and TAVR growth pressures.",
    "url": "https://finnhub.io/api/news?id=68e90228d22de95d07a4db9e9f5188f1e2e55d8b72e3595820fb1f217c5f548c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739344404,
      "headline": "Edwards Lifesciences Corp (EW) Q4 2024 Earnings Call Highlights: Strong Full-Year Growth and ...",
      "id": 132829433,
      "image": "https://media.zenfs.com/en/us.finance.gurufocus/eaf58da0121fd46ca814c36e82d3f964",
      "related": "EW",
      "source": "Yahoo",
      "summary": "Edwards Lifesciences Corp (EW) reports robust 9% sales growth for 2024, driven by TMTT segment and strategic acquisitions, despite regional challenges and TAVR growth pressures.",
      "url": "https://finnhub.io/api/news?id=68e90228d22de95d07a4db9e9f5188f1e2e55d8b72e3595820fb1f217c5f548c"
    }
  }
]